Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F13A1 | P00488 | 10/20 | 0.48 |
| ▸ | TGM1 | P22735 | 4/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7004258 | 0.85 | F13A1 (0.52) | F13A1TGM1NR3C2FABP4TBXA2R | |
| SCHEMBL7002966 | 0.82 | F13A1 (0.52) | F13A1TGM1NR3C2TBXA2R | |
| SCHEMBL7009658 | 0.79 | F13A1 (0.67) | F13A1TGM1NR3C2 | |
| SCHEMBL7005365 | 0.79 | F13A1 (0.67) | F13A1TGM1NR3C2 | |
| SCHEMBL7004697 | 0.76 | F13A1 (0.51) | F13A1TGM1NR3C2 | |
| SCHEMBL7005895 | 0.74 | F13A1 (0.48) | F13A1TGM1NR3C2 | |
| SCHEMBL7010746 | 0.73 | F13A1 (0.48) | F13A1TGM1NR3C2 | |
| SCHEMBL7005641 | 0.72 | F13A1 (0.65) | F13A1TGM1NR3C2 | |
| SCHEMBL7004618 | 0.69 | F13A1 (0.63) | F13A1TGM1NR3C2 | |
| SCHEMBL7009337 | 0.68 | F13A1 (0.78) | F13A1TGM1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1348710-A1 | Sulfonamide derivatives of 3-substituted imidazo[1,2-D]-1,2,4-thiadiazoles and 3-substituted-[1,2,4]thiadiazolo[4,5-A]benzimidazole as inhibitors of fibrin cross-linking and transglutaminases | Apotex Inc. (CA) | 2003-10-01 | — | — | EP | disclosed |